Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783704 | 0.84 | AVPR1A (0.51) | NAMPTPOLBKMT2AALDH1A1MEN1 | |
| SCHEMBL5785896 | 0.83 | NAMPT (0.50) | NAMPTPOLBKMT2AALDH1A1MAPT | |
| SCHEMBL5627464 | 0.83 | AVPR1A (0.47) | NAMPTALDH1A1 | |
| SCHEMBL5626711 | 0.83 | EPHX2 (0.44) | NAMPTCYP1A2CYP2D6CYP2C9ALDH1A1 | |
| SCHEMBL5628198 | 0.82 | AVPR1A (0.40) | NAMPTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5630384 | 0.82 | AVPR1A (0.41) | — | |
| SCHEMBL5627361 | 0.82 | NAMPT (0.45) | NAMPTSMN1; SMN2NPC1CYP1A2CYP3A4 | |
| SCHEMBL5784629 | 0.82 | NAMPT (0.46) | NAMPTPOLBKMT2AALOX15ALDH1A1 | |
| SCHEMBL5626281 | 0.81 | AVPR1A (0.46) | SMN1; SMN2 | |
| SCHEMBL5628387 | 0.80 | TSHR (0.43) | NAMPTSMN1; SMN2ALDH1A1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202239-B2 | Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2007-04-10 | — | — | US | claimed |
| US-20030027815-A1 | Novel cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-02-06 | — | — | US | claimed |
| US-7202239-B2 | Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1377582-A1 | NOVEL 3-C(O)R SUBSTITUTED 10-CYCLOHEXYLBENZOYL PYRROLOBENZODIAZEPINES; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030027815-A1 | Novel cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| WO-2002085907-A1 | NOVEL 3-C(O)R SUBSTITUTED 10-CYCLOHEXYLBENZOYL PYRROLOBENZODIAZEPINES; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027815-A1 | Novel cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, OPRL1, CRHR2 | NAMPT 4023/4885POLB 3362/4885KMT2A 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.